New combo therapy aims to wipe out rectal cancer before surgery

NCT ID NCT06577194

Ongoing Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 11, 2026 · Updated 5 times

Summary

This phase 2 trial tests a new approach for people with locally advanced rectal cancer. Participants first receive a short course of radiation, followed by a combination of immunotherapy (sintilimab and IL-2) and chemotherapy (CAPOX). The goal is to see if this treatment can make the tumor completely disappear before any surgery is needed. The study will enroll 35 adults aged 18 to 70.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sintilimab (PD-1 antibody) plus IL-2 plus CAPOX chemotherapy
What this could lead to: If successful, this combination could increase the chance of complete tumor disappearance before surgery, potentially allowing some patients to avoid surgery altogether.
What could go wrong: This is a small, early-phase trial with only 35 people, so results may not apply broadly. The combination of treatments may cause significant side effects, and it is not yet known if it will improve long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR RECTAL CANCER

Contacts and locations

Locations

Jiangsu Province Hospital

Nanjing, Jiangsu, 210000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.